Zhang Bei, Pei Zhixin, Wang Hongxia, Bai Junjun, Wang Junjie, Zhao Yingxin, Jiang Mei, Wu Huimin, Song Qinglin
Department of Hematology, Jiaozuo People's Hospital, Jiaozuo 454000, China.
Department of Nuclear Medicine, The Second Affiliated Hospital of Henan Polytechnic University, Jiaozuo 454000, China.
J Oncol. 2022 Apr 1;2022:7315879. doi: 10.1155/2022/7315879. eCollection 2022.
To explore the clinical value of specific miRNA in patients with acute promyelocytic leukemia.
129 patients with acute promyelocytic leukemia diagnosed in our hospital from January 2015 to January 2020 were selected as the observation group. At the same time, 74 patients with nonacute promyelocytic leukemia who underwent bone marrow aspiration were included as the control group. The expression levels of miR-126-5p and miR-13, different characteristic parameters, and prognosis were compared between the two groups, and the clinical significance of miR-126-5p and miR-13 in acute promyelocytic leukemia was analyzed.
The expression of miR-126-5p (12.31 ± 2.25 versus 17.30 ± 3.28) and miR-13 (16.05 ± 3.47 versus 21.66 ± 2.18) in the observation group was significantly lower than that in the control group ( < 0.05). The expression level of miR-126-5p was significantly correlated with lactate dehydrogenase level, HGB level, NPM1 mutant type, and complete remission ( < 0.05). The expression level of miR-13 was significantly correlated with HGB level, NPM1 mutant type, and complete remission ( < 0.05). Both expression levels of miR-126-5p and miR-13 were not correlated with sex, age, WBC, PLT, proportion of bone marrow primordial cells, hepatomegaly, splenomegaly, lymph node enlargement, and FLT3-ITD ( > 0.05). Cox multivariate regression analysis showed that peripheral blood WBC, bone marrow blast cell count, and miR-126-5p and miR-13 were prognostic factors in patients with acute promyelocytic leukemia ( < 0.05). The sensitivity, specificity, accuracy, and AUC of serum miR-126-5p prediction were 75.83%, 84.56%, 82.17%, and 0.729, respectively. The sensitivity, specificity, accuracy, and AUC of serum miR-13 prediction were 78.64%, 88.49%, 86.20% and 0.882, respectively.
Serum miR-126-5p and miR-13 are closely related to the prognosis of patients with acute promyelocytic leukemia. Serum miR-126-5p and miR-13 can be used as reliable indexes to predict the prognosis of patients.
探讨特定微小RNA(miRNA)在急性早幼粒细胞白血病患者中的临床价值。
选取2015年1月至2020年1月在我院确诊的129例急性早幼粒细胞白血病患者作为观察组。同时,纳入74例接受骨髓穿刺的非急性早幼粒细胞白血病患者作为对照组。比较两组miR-126-5p和miR-13的表达水平、不同特征参数及预后情况,分析miR-126-5p和miR-13在急性早幼粒细胞白血病中的临床意义。
观察组中miR-126-5p(12.31±2.25 vs 17.30±3.28)和miR-13(16.05±3.47 vs 21.66±2.18)的表达明显低于对照组(P<0.05)。miR-126-5p的表达水平与乳酸脱氢酶水平、血红蛋白水平、核仁磷酸蛋白1(NPM1)突变类型及完全缓解明显相关(P<0.05)。miR-13的表达水平与血红蛋白水平、NPM1突变类型及完全缓解明显相关(P<0.05)。miR-126-5p和miR-13的表达水平均与性别、年龄、白细胞计数、血小板计数、骨髓原始细胞比例、肝肿大、脾肿大、淋巴结肿大及FMS样酪氨酸激酶3内部串联重复(FLT3-ITD)无关(P>0.05)。Cox多因素回归分析显示,外周血白细胞计数、骨髓原始细胞计数以及miR-126-5p和miR-13是急性早幼粒细胞白血病患者的预后因素(P<0.05)。血清miR-126-5p预测的灵敏度、特异度、准确度及曲线下面积(AUC)分别为75.83%、84.56%、82.17%和0.729。血清miR-13预测的灵敏度、特异度、准确度及AUC分别为78.64%、88.49%、86.20%和0.882。
血清miR-126-5p和miR-13与急性早幼粒细胞白血病患者的预后密切相关。血清miR-126-5p和miR-13可作为预测患者预后的可靠指标。